We earn the trust of our LPs, stand with entrepreneurs, and hold ourselves accountable every step of the way.
We do the right thing for the long term. We stay sharp and create value that lasts.
We learn, adapt, and grow. We don't chase trends; we build the edge that sets us apart.
On October 22, Gilead Sciences announced a definitive agreement to acquire PepStar Therapeutics’ oral IL-23R inhibitor program, including lead candidate HCXT-2001, for $1.275 billion in upfront cash consideration.
Agreement includes a $400 million upfront payment and a total potential value of up to $2.13 billion.
LongRiver Investments held its 2026 Annual Conference in Shanghai on September 2, 2026.
LongRiver portfolio company, Ouro Medicines, has entered into a definitive agreement to be acquired by Gilead Sciences.
